AbCellera Biologics Inc. (ABCL)
After hours:
- Simply Wall St.
Analysts Just Shipped A Massive Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders will have a reason to smile today, with the analysts making...
- Motley Fool
Why AbCellera Biologics Is 10% Lower Today
Shares of contract drug developer AbCellera Biologics (NASDAQ: ABCL) are down 10% as of 12:04 p.m. ET today, according to data from S&P Global Market Intelligence, following Piper Sandler's lowered price target despite a seemingly strong earnings report. For the three-month stretch ending March 31, biopharma outfit AbCellera Biologics turned $316.6 million worth of revenue into earnings of $0.54 per share. While AbCellera Biologics' CEO Carl Hansen is unsurprisingly optimistic about the future, that's a future in which the drugs' combined revenue contribution could fade -- significantly.
- Zacks
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
